Samsung Bioepis announced on Wednesday that it will launch an artificial intelligence (AI) competency enhancement program for all employees.
The initiative aims to cultivate AI experts specialized in the biopharmaceutical sector, bolstering the company’s global competitiveness in the era of artificial intelligence.
This marks Samsung Bioepis’ first company-wide AI training program, designed to integrate AI as a core technology for maximizing work efficiency rather than just a supplementary tool.
To support this effort, Samsung Bioepis has established an AI-exclusive training facility dubbed the AI Academy at its Songdo, Incheon headquarters. This dedicated space allows employees to receive ongoing education aligned with rapidly evolving technology trends.
From April to July, approximately 1,000 Samsung Bioepis employees will undergo a minimum of 7 hours of AI theory and hands-on training at the in-house AI center. The curriculum includes leveraging cutting-edge generative AI, developing role-specific AI models, and implementing work automation processes.
To ensure the sustainability of its AI competency enhancement efforts, Samsung Bioepis plans to create a task force led by a dedicated AI team. This group will spearhead the development of tailored AI agents for each division and team within the company.
Samsung Bioepis is also pursuing other technological innovations to stay ahead of industry changes. These initiatives include using digital twin technology to accelerate drug development timelines, building a proprietary AI infrastructure within its secure network, and collaborating with external partners to identify AI-driven drug candidates.
Kang Dae-sung, Executive Director of Samsung Bioepis’ People Team, emphasized that as AI becomes a crucial factor in determining global competitiveness within the biopharmaceutical industry, it is committed to enhancing our employees’ capabilities through these technologies. This investment will ultimately strengthen the company’s core competitiveness in the market.
